SuperworthMyriad Genetics EPS MYGN
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- −$1.19
- Latest quarter, Q2 FY26
- −$0.46
- Fiscal year 2025
- −$3.94
Myriad Genetics' earnings per share was −$1.19 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.46.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.94 | n/a |
| FY2024 | −$1.41 | n/a |
| FY2023 | −$3.20 | n/a |
| FY2022 | −$1.39 | n/a |
| FY2021 | −$0.37 | n/a |
| FY2020 | −$2.68 | n/a |
| FY2020 | −$2.99 | −6080% |
| FY2019 | $0.05 | −97% |
| FY2018 | $1.88 | +527% |
| FY2017 | $0.30 | −82% |
| FY2016 | $1.70 | +57% |
| FY2015 | $1.08 | −52% |
| FY2014 | $2.25 | +27% |
| FY2013 | $1.77 | +36% |
| FY2012 | $1.30 | +17% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.46 | n/a | −$1.19 | |
| Q1 FY26 | −$0.36 | n/a | −$4.30 | |
| Q4 FY25 | −$0.08 | n/a | −$3.94 | |
| Q3 FY25 | −$0.29 | n/a | −$4.33 | |
| Q2 FY25 | −$3.57 | n/a | −$4.28 | |
| Q1 FY25 | $0.00 | n/a | −$1.12 | |
| Q4 FY24 | −$0.47 | n/a | −$1.41 | |
| Q3 FY24 | −$0.24 | n/a | −$1.30 | |
| Q2 FY24 | −$0.41 | n/a | −$1.81 | |
| Q1 FY24 | −$0.29 | n/a | −$2.82 | |
| Q4 FY23 | −$0.36 | n/a | −$3.20 | |
| Q3 FY23 | −$0.75 | n/a | −$3.36 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Myriad Genetics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MYGNMyriad Genetics | −$1.19 | |
| NRCNRC Health | $0.25 | −67% a year |
| ICCCImmucell | $0.08 | −58% a year |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| BLLNBillionToOne | $0.65 | |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Myriad Genetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.